We have a successful MSO rolling into our expansion phase. Our model allows us to cut time to payback by 2 years, without needing full integration. Our rocket fuel is a growing TAM (about 2M new customers a year) projected until 2030. We specifically target businesses with 10%-12% EBITDA margins with the proper patient mix to yield 26% - 34% EBITDA blend post-acquisition (a 16% - 22% EBITDA margin improvement) You are welcome to connect or email me directly at --@----.com
To download teaser or contact poster, please sign in.